The third phase of the "Oxford New Crown Vaccine" test in the UK has resumed

, Sept. 12 (Xinhua Zhang Ping) Britain's AstraZenecom spokesman announced on the 12th, by the University of Oxford and AstraZeneta Co. jointly developed the "Oxford New Crown Vaccine", the United Kingdom's safety regulator approved the resumption of clinical trials.
spokesman for AstraZeneta uk said the vaccine review
's safety examiner had advised the UK Medicines and Health Products Agency (MHRA) that it was safe to resume testing the vaccine. After approval, the company has resumed clinical trials of the vaccine in the UK. The spokesman said the vaccine is one of the most advanced in the world.
same time, Oxford University said in a statement that the independent review process for the vaccine had been completed. As recommended by
and the UK Medicines and Health Products Agency, the third phase of the vaccine trial will resume at all clinical sites across the country.
8 September, the vaccine, called AZD1222, was suspended in the third phase of human testing after a British volunteer developed a "serious adverse reaction" that could have been caused by the vaccine. According to media reports, the volunteer developed neurological symptoms associated with rare spinal corditis.
Sir Jeremy Farrar, chairman of the Wellcome Trust, a member of the UK government's Scientific Advisory Group on Emergencies, said: "For me, the right procedures for vaccine testing, the involvement of independent regulators and temporary suspensions are crucial. Matt Hancock,
health secretary, said it was gratifying and expected that the vaccine would resume its third phase of trials, "and in the best case, the vaccine could be launched by the end of the year." I think next year is more likely, the first few months of next year are the most likely. "(Complete)